New insights into thyroid hormone replacement therapy

Brenda M. Acosta, Antonio C. Bianco

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

It is widely accepted that thyroid hormone replacement for patients with hypothyroidism can be fully accomplished with levothyroxine monotherapy, as assessed by serum thyroid function tests. However, approximately 10% of hypothyroid patients are dissatisfied with the outcome of levothyroxine monotherapy, and physicians continue to report benefits from combined levothyroxine-triidothyronine therapy for some hypothyroid patients. Recently, a large prospective study reported that the benefit of the combined levothyroxine-triidothyronine therapy is associated with the Thr92Ala polymorphism in the type 2 deiodinase gene, which is present in about 15% of the general population. If confirmed, these findings indicate that personalized medicine is rapidly catching up with modern thyroidology.

Original languageEnglish
Article number34
JournalF1000 Medicine Reports
Volume2
Issue number1
DOIs
StatePublished - May 11 2010

Fingerprint

Hormone Replacement Therapy
Thyroxine
Thyroid Hormones
Thyroid Function Tests
Iodide Peroxidase
Precision Medicine
Hypothyroidism
Prospective Studies
Physicians
Therapeutics
Serum
Population
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

New insights into thyroid hormone replacement therapy. / Acosta, Brenda M.; Bianco, Antonio C.

In: F1000 Medicine Reports, Vol. 2, No. 1, 34, 11.05.2010.

Research output: Contribution to journalArticle

Acosta, Brenda M. ; Bianco, Antonio C. / New insights into thyroid hormone replacement therapy. In: F1000 Medicine Reports. 2010 ; Vol. 2, No. 1.
@article{9e220aa22f0b4b01ba6c02aa3f059038,
title = "New insights into thyroid hormone replacement therapy",
abstract = "It is widely accepted that thyroid hormone replacement for patients with hypothyroidism can be fully accomplished with levothyroxine monotherapy, as assessed by serum thyroid function tests. However, approximately 10{\%} of hypothyroid patients are dissatisfied with the outcome of levothyroxine monotherapy, and physicians continue to report benefits from combined levothyroxine-triidothyronine therapy for some hypothyroid patients. Recently, a large prospective study reported that the benefit of the combined levothyroxine-triidothyronine therapy is associated with the Thr92Ala polymorphism in the type 2 deiodinase gene, which is present in about 15{\%} of the general population. If confirmed, these findings indicate that personalized medicine is rapidly catching up with modern thyroidology.",
author = "Acosta, {Brenda M.} and Bianco, {Antonio C.}",
year = "2010",
month = "5",
day = "11",
doi = "10.3410/M2-34",
language = "English",
volume = "2",
journal = "F1000 Medicine Reports",
issn = "1757-5931",
publisher = "Medicine Reports Limited",
number = "1",

}

TY - JOUR

T1 - New insights into thyroid hormone replacement therapy

AU - Acosta, Brenda M.

AU - Bianco, Antonio C.

PY - 2010/5/11

Y1 - 2010/5/11

N2 - It is widely accepted that thyroid hormone replacement for patients with hypothyroidism can be fully accomplished with levothyroxine monotherapy, as assessed by serum thyroid function tests. However, approximately 10% of hypothyroid patients are dissatisfied with the outcome of levothyroxine monotherapy, and physicians continue to report benefits from combined levothyroxine-triidothyronine therapy for some hypothyroid patients. Recently, a large prospective study reported that the benefit of the combined levothyroxine-triidothyronine therapy is associated with the Thr92Ala polymorphism in the type 2 deiodinase gene, which is present in about 15% of the general population. If confirmed, these findings indicate that personalized medicine is rapidly catching up with modern thyroidology.

AB - It is widely accepted that thyroid hormone replacement for patients with hypothyroidism can be fully accomplished with levothyroxine monotherapy, as assessed by serum thyroid function tests. However, approximately 10% of hypothyroid patients are dissatisfied with the outcome of levothyroxine monotherapy, and physicians continue to report benefits from combined levothyroxine-triidothyronine therapy for some hypothyroid patients. Recently, a large prospective study reported that the benefit of the combined levothyroxine-triidothyronine therapy is associated with the Thr92Ala polymorphism in the type 2 deiodinase gene, which is present in about 15% of the general population. If confirmed, these findings indicate that personalized medicine is rapidly catching up with modern thyroidology.

UR - http://www.scopus.com/inward/record.url?scp=77955062507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955062507&partnerID=8YFLogxK

U2 - 10.3410/M2-34

DO - 10.3410/M2-34

M3 - Article

C2 - 20948851

AN - SCOPUS:77955062507

VL - 2

JO - F1000 Medicine Reports

JF - F1000 Medicine Reports

SN - 1757-5931

IS - 1

M1 - 34

ER -